Home
    Disclaimer
    Phenethylamine molecular structure

    Phenethylamine Stats & Data

    Pea Benzeneethanamine Beta-phenylethylamine
    NPS DataHub
    MW121.18
    FormulaC8H11N
    CAS64-04-0
    LD50300.0 mg/kg (Rat 300 mg/kg; Merck)
    IUPAC2-phenylethanamine
    SMILESNCCc1ccccc1
    InChIKeyBHHGXPLMPWCGHP-UHFFFAOYSA-N
    Phenethylamines
    Chemical Class Phenethylamine
    Psychoactive Class Stimulant
    Half-Life Minutes (very short; dominated by rapid MAO-B metabolism).

    Pharmacology

    DrugBank
    State Solid

    Description

    Pea allergenic extract is used in allergenic testing.

    Receptor Profile

    Receptor Actions

    Agonists
    TAAR1 agonist (trace amine-associated receptor 1)
    Inhibitors
    VMAT2 inhibitor (vesicular monoamine transporter 2)

    History & Culture

    Phenethylamine has long held a special place in psychopharmacological research due to its status as the simplest member of the phenethylamine chemical class. Its clean molecular structure, natural presence in human tissues and bodily fluids, and close chemical relationship to both amphetamine and endogenous neurotransmitters have made it a subject of sustained scientific interest. The compound occurs widely throughout nature in both plants and animals, produced as a metabolic byproduct during the bacterial decomposition of phenylalanine in tissue. Multiple synthetic routes for phenethylamine were established in the mid-twentieth century. In 1948, R. F. Nystrom and W. G. Brown first reported a convenient synthesis involving the reduction of ω-nitrostyrene using lithium aluminium hydride in ether. An alternative method was later published in 1955 by J. C. Robinson and H. R. Snyder in Organic Syntheses, which employed the reduction of benzyl cyanide with hydrogen in liquid ammonia using a Raney-Nickel catalyst under high temperature and pressure conditions. Phenethylamine gained popular attention through its association with chocolate, where it occurs as a significant component, particularly following microbial fermentation. This led to its characterization in mainstream media as "the love-sickness chemical," spawning a popular myth that individuals experiencing heartbreak compulsively consume chocolate to replenish depleted phenethylamine levels. While some researchers have speculated that phenethylamine may play a role in romantic affection, these claims have not been substantiated by direct experimental evidence. The compound has also been implicated in the euphoric effects of vigorous physical activity; research has demonstrated that thirty minutes of moderate- to high-intensity exercise significantly elevates urinary levels of phenylacetic acid, the primary metabolite of phenethylamine. Similar increases have been observed following skydiving, suggesting phenethylamine may contribute to the subjective pleasure associated with intense physical exertion.

    Effect Profile

    Curated + 13 Reports
    Stimulant 5.6

    Strong anxiety/jitters with moderate euphoria and focus, mild stimulation

    Stimulation / Energy×3
    5
    Euphoria / Mood Lift×2
    7
    Focus / Productivity×2
    7
    Anxiety / Jitters×1
    8

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Minutes (very short; dominated by rapid MAO-B metabolism).
    Addiction Potential
    Low physiological dependence potential; however, the very short duration can promote binge/redose patterns in some individuals, particularly when potentiated by MAO-B inhibitors.

    Tolerance Decay

    Full tolerance 1d Half tolerance 3d Baseline ~7d

    Data are anecdotal; users frequently report rapid loss of effect with repeated dosing in a session and partial return to baseline sensitivity after several days to a week.

    Cross-Tolerances

    Other stimulants (indirect sympathomimetics)
    30% ●○○

    Experience Report Analysis

    Erowid
    13 Reports
    2008–2024 Date Range
    11 With Age Data
    12 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 13 experience reports (13 Erowid)

    13 Reports
    12 Effects Detected
    6 Positive
    5 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 6

    Euphoria 53.8% 70%
    Tactile Enhancement 46.2% 70%
    Body High 38.5% 70%
    Focus Enhancement 38.5% 70%
    Stimulation 38.5% 70%
    Empathy 30.8% 70%

    Adverse Effects 5

    Anxiety 46.2% 70%
    Nausea 30.8% 70%
    Sweating 23.1% 70%
    Confusion 23.1% 70%
    Muscle Tension 23.1% 70%

    Real-World Dose Distribution

    62K Doses

    From 19 individual dose entries

    Oral (n=10)

    Median: 1000.0mg 25th: 425.0mg 75th: 1237.5mg 90th: 3100.0mg
    mg/kg median: 15.204 mg/kg 75th: 31.691

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Harm Reduction

    drugs.wiki

    - PEA is preferentially metabolized by monoamine oxidase-B (MAO-B), leading to a very short duration and low oral bioavailability; any MAO-B inhibition can dramatically increase exposure and physiological impact. This is the central harm-reduction issue: avoid all MAOIs (including Parkinson’s drugs and the antibiotic linezolid).

    - Selective MAO-B inhibitors (selegiline, rasagiline, safinamide) and nonselective/irreversible MAOIs (phenelzine, tranylcypromine, isocarboxazid) can potentiate PEA to a degree that risks severe hypertension, hyperthermia, or cerebrovascular events; this risk exists even at small PEA doses when MAO is inhibited.

    - Linezolid is a reversible, nonselective MAOI used as an antibiotic; combining PEA with linezolid can precipitate dangerous pressor responses and should be strictly avoided.

    - Because the psychoactive window is brief, some users escalate to gram-level oral doses or engage in frequent redosing cycles; harm-reduction priorities include not stacking stimulants, monitoring blood pressure/heart rate, maintaining hydration, and stopping at the first signs of severe headache, chest pain, or marked flushing. These redosing patterns are consistently reported in harm-reduction forums and align with the known indirect sympathomimetic profile of PEA.

    - PEA primarily acts as an endogenous trace amine/TAAR1 agonist and an indirect sympathomimetic (catecholamine-releasing); expect tachycardia, blood pressure elevation, and anxiety at higher doses, especially with co-stimulants. Individuals with cardiovascular disease should avoid use.

    - Food-derived/background PEA (e.g., chocolate) is trivial compared to supplemental doses; however, in the presence of MAOI therapy even trace amines can become clinically significant, reinforcing the strict MAOI-avoidance guidance.

    - Urine drug testing: cross-reactivity data indicate β-phenethylamine can interfere with some assays; although not usually targeted, unexpected results should be confirmed with specific methods (e.g., GC/MS).

    - There is no established therapeutic dosing for psychoactive purposes. If an individual nevertheless chooses to experiment, conservative spacing (weeks) and strict avoidance of MAOIs and stimulant stacks are critical to reduce cumulative cardiovascular strain and compulsive redosing risk.

    ← Back to Phenethylamine